<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333732</url>
  </required_header>
  <id_info>
    <org_study_id>202004099</org_study_id>
    <nct_id>NCT04333732</nct_id>
  </id_info>
  <brief_title>CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION</brief_title>
  <acronym>CROWN CORONA</acronym>
  <official_title>An International, Multi-site, Bayesian Platform Adaptive,Randomised, Double-blind, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthcare workers are at the frontline of the fight against COVID-19, and as such they are
      at high risk for infection and possibly for serious infection, linked to the extent of their
      exposure. The CROWN CORONATION trial prioritizes the protection of healthcare workers as a
      strategy to prevent collapse of healthcare services.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CROWN CORONATION is a large, Bayesian adaptive, pragmatic, participant-level randomized,
      multi-center, transdisciplinary, international placebo-controlled trial. It has been designed
      in accordance with CONSORT guidelines. Randomization will be stratified by age (&lt;50 and &gt;50)
      and site. Participants will be healthcare workers at risk for contracting SARS-CoV-2.
      Participants will be randomized into one of four arms:

        -  Low-dose (300mg chloroquine base weekly);

        -  Medium-dose (300mg chloroquine base twice weekly);

        -  High-dose (150 mg chloroquine base daily);

        -  Placebo.

      In all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of
      placebo tablets in the placebo arm) will be taken in 4 divided daily doses (that is 300mg
      chloroquine base per day for four days) before starting the low, medium, or high dose
      regimen.

      New dosage-based arm(s) might be added or removed. The trial will evaluate which of the
      intervention arms is most effective at decreasing the incidence of severe COVID-19 disease,
      without unacceptable side effects or safety events.

      Participants will complete weekly (smart phone- based) data logs, and follow- up information
      will be collected until 2 months after enrollment or death. In addition, where possible, we
      will use telemedicine approaches to collection information on participants. We will provide
      adherence support interventions that have worked and been tested for Human Immunodeficiency
      Virus Pre-Exposure Prophylaxis (HIV PrEP) (e.g. two-way SMS with check in for those that
      report symptoms or adverse events). On enrollment, the local trial team will create a new
      electronic case record from (CRF) on the web-based study database and record basic
      demographic information. Participants will be given a secure login to enable them to complete
      an initial participant health questionnaire and the daily data logs.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A international, multi-site, randomized, double-blinded, placebo-controlled clinical effectiveness</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic COVID-19</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the effectiveness (and minimum effective dose schedule) of chloroquine prophylaxis in preventing laboratory-confirmed symptomatic, laboratory test-confirmed COVID-19 (WHO COVID-19 severity scale score &gt;1) in healthcare workers with repeated exposures to SARS-CoV-2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak severity of COVID-19 over the study period</measure>
    <time_frame>3 months</time_frame>
    <description>i) Uninfected - no clinical or virological evidence of infection (Score = 0) ii) Ambulatory - no limitation of activities (score=1) or with limitation (Score=2) iii) Hospitalized - mild no oxygen (Score=3) or with oxygen (Score=4) iv) Hospitalized severe - Scores 5-7* v) Dead
* Score 5 is non-invasive ventilation or high flow oxygen; Score 6 is intubation with mechanical ventilation; Score 7 is intubation with additional organ support (e.g. pressors, renal replacement therapy, extra corporeal membrane oxygenation [ECMO]) These outcome definitions are based on WHO R&amp;D Blueprint consensus definitions for COVID-19.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55000</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Low-dose (300mg chloroquine base weekly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine base 300 mg administered orally as chloroquine once weekly. The decision of whether to offer chloroquine will be based on local availability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose (300mg chloroquine base twice weekly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine base 300 mg administered orally as chloroquine twice weekly. The decision of whether to offer chloroquine will be based on local availability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose (150 mg chloroquine base daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine base 150 mg administered orally once daily either a chloroquine . The decision of whether to offer chloroquine will be based on local availability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 - 1 placebo tablet administered orally once daily, Placebo 2 - two placebo tablets administered orally twice weekly, Placebo 3 - two placebo tablets administered orally once weekly. All Placebo groups will take two placebo tablets daily on day 1, day 2, day 3 and day 4, before continuing to a daily, twice weekly or weekly schedule to complete 3 months of administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose chloroquine</intervention_name>
    <description>chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate) weekly
In all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.</description>
    <arm_group_label>Low-dose (300mg chloroquine base weekly)</arm_group_label>
    <other_name>Aralen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid-dose chloroquine</intervention_name>
    <description>chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate) twice weekly
In all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.</description>
    <arm_group_label>Medium-dose (300mg chloroquine base twice weekly)</arm_group_label>
    <other_name>Aralen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose chloroquine</intervention_name>
    <description>chloroquine base 150mg (equivalent to 250mg chloroquine phosphate or 200mg chloroquine sulphate) daily
In all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.</description>
    <arm_group_label>High-dose (150 mg chloroquine base daily)</arm_group_label>
    <other_name>Aralen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo equivalent of low, medium and high arm. Low- once weekly Medium - twice weekly High - daily
In all treatment arms, an induction dose of 1200mg chloroquine or base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Volunteers without clinical evidence of COVID-19 infection aged 18 years and older.

          2. Healthcare workers based in a primary, secondary or tertiary healthcare setting with a
             high risk of developing COVID-19 due to their potential exposure to patients with
             SARS-CoV-2 infection.

          3. Must have a mobile phone and access to the internet for data collection purposes.

          4. Participants who are willing and able to provide informed consent via an electronic
             consent process.

        Exclusion criteria

          1. Weight outside range 50 kg - 120 kg (110 lbs - 265 lbs).

          2. Prior enrolment into this or other COVID-19 interventional prevention or treatment
             trials (observational trials not excluded).

          3. Self-reported or diagnosed current infection with SARS-CoV-2 or previous COVID-19
             diagnosis.

          4. Self-reported current acute respiratory infection.

          5. Concurrent and/or recent involvement in other research or use of
             chloroquine/hydroxychloroquine or any other 4-aminoquinolone or another experimental
             investigational medicinal product that is likely to interfere with the study
             medication within three months of study enrolment.

          6. Current use of antimalarial agents (lumefantrine, mefloquine, pyronaridine or
             amodiaquine) or any other drugs that may cause a dangerous drug interaction as listed
             in Appendix 3.

          7. Self-reported known allergies to the IMP and excipients of IMP and placebo.

          8. Self-reported presence or history of the following conditions: Retinopathy or retinal
             disease; Cardiomyopathy (structural or ischemic heart disease); Cardiac arrhythmia;
             known personal or family history of prolonged QTc; Psoriasis; Porphyria cutanea tarda;
             Epilepsy; Myasthenia gravis; Myopathy of any cause; Serious hepatic or renal disease;
             Electrolyte abnormalities; self-reported severe depression or suicidality; currently
             undergoing treatment for tuberculosis.

          9. Self-reported current use of medication with known serious hepatotoxic effects or
             known interaction with chloroquine as listed in Appendix 3, including anti-TB
             treatment

         10. Self-reported use of medications which prolong the QTc interval

         11. Inability or unwillingness to be followed up for the trial period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S. Avidan, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univeristy School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramani Moonesinghe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Rees, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wits University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Yun, BS</last_name>
    <phone>314-273-2240</phone>
    <email>lindayun@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry McKinnon, BS</last_name>
    <phone>314-286-1768</phone>
    <email>smckinnon@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Linda Yun, BS</last_name>
      <phone>314-273-2240</phone>
      <email>lindayun@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sherry McKinnon</last_name>
      <phone>314-286-1768</phone>
      <email>mckinnos@anest.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael S. Avidan, MBBCh, FCASA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Politi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Dubberke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Population Health Resarch Institute</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jessica Spence, MD, FRCPC</last_name>
      <email>spencej@phri.ca</email>
    </contact>
    <investigator>
      <last_name>Jessica Spence, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>David Mazer, MD</last_name>
      <phone>(416) 864-5825</phone>
      <email>David.Mazer@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>David Mazer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Leinster</state>
        <zip>Dublin 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ellen O'Sullivan, MD, FRCA,FCAI</last_name>
      <phone>353876993178</phone>
      <email>ellenosullivan2000@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitas Academic Hospital</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Edwin Turton, MBChB, Dip PEC, DA, MMed, FCA</last_name>
      <phone>+27 82 804 6839</phone>
      <email>turtonew@ufs.ac.za</email>
    </contact>
    <investigator>
      <last_name>Edwin Turton, MBChB, Dip PEC, DA, MMed, FCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wits RHI, University of the Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Sinead Delany-Moretlwe, MBChB, PhD, DTM&amp;H</last_name>
      <phone>+27 82 377 6275</phone>
      <email>sdelany@wrhi.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Moorhouse, MBChB</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gloria Maimela, MBBCh MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saiqa Mullick, MBBCh PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Martin, MBBCh MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Steve Biko Academic Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie Mathijs, MBChB, MPharmMed</last_name>
      <phone>+27 836506425</phone>
      <email>sandra.spijkerman@up.ac.za</email>
    </contact>
    <investigator>
      <last_name>Sophie Mathijs, MBChB, MPharmMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Coenraad Koegelenberg, MBChB, MMED, FCP, MRCP, PhD</last_name>
      <phone>+27 833201307</phone>
      <email>coeniefn@sun.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Sean Chetty, MBChB, FCA, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Coenraad Koegelenberg, MBChB, MMED, FCP, MRCP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Chetty, MBChB, FCA, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurence Lovat, MD, PhD</last_name>
      <phone>020 3447 7488</phone>
      <email>laurence.lovat@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Laurence Lovat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakim-Moulay Dehbi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nick Freemantle, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dermot McGuckin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Jones, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramani Moonesinghe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levy Mwanawasa University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <zip>10101</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <contact>
      <last_name>Laston Chikoya, BSc, MBChB, MMed, MD</last_name>
      <phone>+260977349415</phone>
      <email>chikoyal@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Bright Nsokolo, BScHB, MB ChB, MMED</last_name>
      <phone>+260977884895</phone>
      <email>b_nsokolo@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Izukanji Sikazwe, MBChB, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roma Chilengi, MBChB, MSc, ACCRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bolton, MBBCh, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chikumbutso Chipeta, BScHB, MB ChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bright Nsokolo, BScHB, MB ChB, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lloyd Mulenga, BScHB, MBCHB, MScID, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia [CIDRZ]</name>
      <address>
        <city>Lusaka</city>
        <zip>H8R9+9V</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <contact>
      <last_name>Izukanji Sikazwe</last_name>
    </contact>
    <investigator>
      <last_name>Izukanji Sikazwe</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roma Chilengi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bolton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chikumbutso Chipeta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Ireland</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Zambia</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Michael Avidan</investigator_full_name>
    <investigator_title>Professor of Anesthesiology and Surgery</investigator_title>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>Health care workers</keyword>
  <keyword>chloroquine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the main publication may be shared, after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From 3 months after the last patient last visit onward.</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

